Justices Struggle With BPCIA Enigma

By Tasha Francis and Jenny Shmuel, Fish & Richardson PC (April 27, 2017, 6:19 PM EDT) -- Oral arguments were heard on Wednesday in the landmark Amgen Inc. v. Sandoz Inc. case before the U.S. Supreme Court. This is the high court's first opportunity to weigh in on the Biologics Price Competition and Innovation Act, legislation creating an abbreviated regulatory pathway for biosimilars and a framework for resolving associated patent disputes. The case has garnered considerable public interest, with numerous amici briefs filed, including a brief filed by the United States....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!